The Melia Lab is excited for #CellBio2022! Check out posters by our awesome grad students at the Autophagy session on Sunday (Devin Fuller B577 and Emily B578) and Establishing and Maintaining Organelle Structure on Monday (Taryn Olivas B433 and Justin Korfhage B432). (1/2)

Come hear my talk on Monday at 11:15 in room 201 where I’ll share my work demonstrating ATG2A mediated lipid transport at a phospholipid monolayer, and come find my poster at B432 #CellBio2022

Tom (Melia Lab) and I recently had the privilege of highlighting recent work out of Elazar lab: check out our news and views article here! 1/3 doi.org/10.15252/embj.…

“The man on the middle cross said I can come.” Gospel gold from Alistair Begg.

Our study on #lipiddroplets and #autophagy is out now! We found that Atg3 targets specific LDs during prolonged starvation to lipidate LC3B, promoting noncanonical autophagy processes. Great collaboration with Melia Lab.🙏Fondation pour la Recherche Médicale for the support. sciencedirect.com/science/articl…

Scientists are more like regular people than they pretend. The vast majority of their views, that shape their politics, and day-to-day life, are based on no better evidence than anyone else's. Only a tiny sliver of their life is informed by unique knowledge.

Human centered architecture and city planning m.youtube.com/watch?v=wrnAsM…

If you like #genetics in human cells you may enjoy our latest paper by Gianluca Talevi and collaborators. A ‘fishing expedition’ using logic as our guide by Gian-Luca McLelland to study triglyceride synthesis. After some plot twists it yields DIESL! nature.com/articles/s4158…

Faa1 membrane binding drives positive feedback in autophagosome biogenesis via fatty acid activation biorxiv.org/cgi/content/sh… #bioRxiv

With many PhDs in biomedical science heading toward pharmaceutical careers, it’s important for even basic researchers to understand statistical nuances in the clinical setting. Great lecture!

HAIL TO THE VICTORS, THE WOLVERINES ARE NATIONAL CHAMPIONS 🏆 #NationalChampionship

EPIC-SR trial: In fully vaccinated patients with risk factors for severe disease and patients (vaccinated or unvaccinated) without such risk factors, nirmatrelvir–ritonavir did not significantly shorten the time to alleviation of Covid-19 symptoms. nej.md/49kLhq3

Pfizer's EPIC-SR study is (finally) published (what took this so long?). 1: Primary finding: No benefit from Paxlovid on symptom alleviation among vaccinated or unvaccinated people.

Just adding my two cents: I happily support Jay Bhattacharya as a candidate for leading NIH. He has the right multi-disciplinary training & admirable commitment to rational science & deliberative policy-making. He is superbly qualified for such a post. washingtonpost.com/health/2024/11…